Cancer Biology & Medicine

►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".


►►Very important notification on publication fee

Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.

Cancer Biology & Medicine

Cancer Biology & Medicine is a peer-reviewed open-access journal published by the China Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:

● Cancer genetics

● Cancer and stem cell biology

● Molecular and clinical immunology

● Cancer prevention and epidemiology

● Cancer biomarkers

● Radiation oncology

● Oncology clinical trials

● Mechanisms of drug sensitivity and resistance

● Targeted therapy and immunotherapy

● Multidisciplinary treatment and personalized medicine

Author Benefits

● Easy submission via online system

● Efficient and professional peer review

● Rapid pre-print online publication

● No charge for publication and open access

● International visibility-All full texts are free in PubMed Central




Publication of the 2nd issue in 2020


In this issue, advances in the role of ABC transporters, four and a half LIM domains protein 1, and mechanical microenvironment in tumorigenesis and cancer development have been displayed in several reviews. The review written by Prof. Yun Niu focuses on special histological types and emerging therapeutic methods for triple negative breast cancer.

Original researches on clinical oncology refer to MRI-guided and targeted theranostics of colorectal cancer, higher recurrence risk after microwave ablation in hepatocellular carcinoma patients with cholecystectomy, related studies on advanced non-small cell lung cancer and osteogenic sarcoma, and so on. Application of cancer nano-technology and the roles of some molecules and signaling pathways in cancer progression have also been included.

Just as before, we hope the fruitful contents in this issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine.

Posted: 2020-05-18

Publication of the 1st issue in 2020


The two editorials are both related to precision oncology. Professor Yu and Wei comment on the Human Pan-genome Analysis system (HUPAN) which could be used in determining differences between individual genomes and whether these differences are related to cancer susceptibility. Another editorial contributed by Professor Zhang and You focuses on CRISPR-Cas13a system that has been found to effectively inhibit tumor growth and angiogenesis in an intracranial glioma model.

Reviews and original articles in this issue revealed that some molecules such as N6-methyladenosine, COX-2, CDK11, play important roles in tumorigenesis and development of cancer. Besides, other clinical research reported new findings in diagnosis and treatment for gastric cancer, esophageal cancer, nasopharyngeal carcinoma, and ovarian cancer.

We hope the content of this issue will greatly benefit your research and clinical practice. Thank you for your attention and welcome to submit your work to Cancer Biology & Medicine.

Posted: 2020-02-14
More Announcements...

Vol 17, No 1: February 2020

Table of Contents


A powerful HUPAN on a pan-genome study: significance and perspectives PDF
Yingyan Yu, Chaochun Wei 1-5
CRISPR-Cas13a system: a novel approach to precision oncology PDF
Junxia Zhang, Yongping You 6-8


Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer PDF
Zhixian Liang, Reilly L. Kidwell, Haijing Deng, et al. 9-19
COX-2 as a potential biomarker and therapeutic target in melanoma PDF
Diana Valentina Tudor, Ioana Bâldea, Mihai Lupu, et al. 20-31
Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment PDF
Yuting Zhang, Guoqiang Liu, Miaomiao Sun, et al. 32-43
Metabolic reprogramming in triple-negative breast cancer PDF
Zhanyu Wang, Qianjin Jiang, Chenfang Dong 44-59

Original Article

Preparation, characterization, pharmacokinetics and anticancer effects of PEGylated β-elemene liposomes PDF
Bingtao Zhai, Qibiao Wu, Wengang Wang, et al 60-75
Identification of a potential tumor suppressor gene, UBL3, in non-small cell lung cancer PDF
Xinchun Zhao, Yongchun Zhou, Qian Hu, et al. 76-87
27-Hydroxycholesterol-induced EndMT acts via STAT3 signaling to promote breast cancer cell migration by altering the tumor microenvironment PDF
Kailin Jiao, Jing Zhen, Maoxuan Wu, et al. 88-100
MicroRNA-6744-5p promotes anoikis in breast cancer and directly targets NAT1 enzyme PDF
Sharan Malagobadan, Chai San Ho, Noor Hasima Nagoor 101-111
Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway PDF
Yulong Lan, Jiacheng Lou, Jiliang Hu, et al. 112-131
Synthetic and immunological studies on the OCT4 immunodominant motif antigen-based anti-cancer vaccine PDF
Tingting Chen, Kan Liu, Jiangyao Xu, et al. 132-141
The role of bone marrow-derived cells in the origin of liver cancer revealed by single-cell sequencing PDF
Lu Chen, Xianfu Yi, Piao Guo, et al. 142-153
Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis PDF
Caijun Zha, Xiangqi Meng, Lulu Li, et al 154-168
Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance PDF
Jiaojiao Zhou, Xuan Zhu, Shijie Wu, et al. 169-180
A systematic review of metabolomic profiling of gastric cancer and esophageal cancer PDF
Sha Huang, Yang Guo, Zhexuan Li, et al. 181-198
Clinical characteristics and work-up of small to intermediate-sized pulmonary nodules in a Chinese dedicated cancer hospital PDF
Xiaonan Cui, Daiwei Han, Marjolein A. Heuvelmans, et al. 199-207
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma PDF
Olivia Leblanc, Sophie Vacher, Charlotte Lecerf, et al 208-217
Characterization of 500 Chinese patients with cervical esophageal cancer by clinicopathological and treatment outcomes PDF
Peinan Chen, Xueke Zhao, Fuyou Zhou, et al 218-226
Establishment of a prognostic scoring model for regional recurrent nasopharyngeal carcinoma after neck dissection PDF
Xiaoyun Li, Chao Lin, Jinjie Yan, et al. 227-236
The role of a drug-loaded poly (lactic co-glycolic acid) (PLGA) copolymer stent in the treatment of ovarian cancer PDF
Yanqing Wang, et al, Xiaoyin Qiao, Xiao Yang, et al. 237-250


Erratum to Inactivation of FOXO1 induces T follicular cell polarization and involves angioimmunoblastic T cell lymphoma PDF
Meifang Xu, Fei Wang, Hong Chen, et al. 251
Erratum to Circular RNAs and human glioma PDF
Jinglei Liu, Kun Zhao, Nunu Huang, et al. 252